Article Text

Download PDFPDF

Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
  1. A. Du Bois*,,
  2. J. Rochon,
  3. C. Lamparter§ and
  4. J. Pfisterer,
  1. * Dept. Gynaecology & Gynaecologic Oncology, HSK Wiesbaden, Germany, University Schleswig-Holstein, Campus Kiel, Germany
  2. Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Organkommission OVAR, Germany, University Schleswig-Holstein, Campus Kiel, Germany
  3. KKS University Marburg, Germany, University Schleswig-Holstein, Campus Kiel, Germany
  4. § MMF Herdecke, Germany, University Schleswig-Holstein, Campus Kiel, Germany
  5. Dept. Obstetrics & Gynaecology, University Schleswig-Holstein, Campus Kiel, Germany
  1. Address correspondence and reprint requests to: Prof. Dr Andreas du Bois, Dept. Gynaecology & Gynaecologic Oncology, Dr Horst-Schmidt-Kliniken (HSK), Ludwig-Erhard-Strasse 100, D-65199 Wiesbaden, Germany. Email: dubois.hsk-wiesbaden{at}uumail.de

Abstract

The purpose of this study was to evaluate the pattern and quality of care for ovarian cancer in Germany and analyze prognostic factors with emphasis on characteristics of treating institutions, hospital volume, and participation in clinical trials. This study utilized national survey including patients with histologically proven invasive epithelial ovarian cancer diagnosed in the third quarter of 2001 including descriptive analysis of pattern of surgical care and systemic treatment in early (FIGO I–IIA) and advanced (FIGO IIB–IV) ovarian cancer and both univariate and multivariate analysis of prognostic factors. One third of all patients diagnosed in the third quarter of 2001 in Germany, 476 patients, were included. Standard care according to German guidelines was provided to only 35.5% of patients with early ovarian cancer. Recommended chemotherapy was given to 78% in advanced disease. Multivariate analysis showed advanced stage, poor performance status, comorbidity, ascites, and treatment in an institution not participating in cooperative studies to be associated with inferior survival. Non-participation was associated with an 82% increase of risk (HR = 1.82; 95% CI, 1.27–2.61; P = 0.001). Hospital volume did not affect treatment outcome. Adherence to treatment guidelines showed remarkable variety among German hospitals, indicating options and need for improvement. Selecting an institution that participates in cooperative trials might be an option for individual patients seizing the chance for better quality of care even when individual factors might hamper enrollment in a study.

  • guideline
  • hospital volume
  • ovarian neoplasm
  • pattern of care
  • quality of care
  • study participation

Statistics from Altmetric.com

Footnotes

  • None of the authors had any conflict of interests regarding the present work.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.